Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Non-current Assets to Total Assets Ratio for the year ending December 31, 2023: 0.02

Third Harmonic Bio Inc. Non-current Assets to Total Assets Ratio is 0.02 for the year ending December 31, 2023, a -3.04% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Third Harmonic Bio Inc. Non-current Assets to Total Assets Ratio for the year ending December 31, 2022 was 0.02, a 0.00% change year over year.
Third Harmonic Bio Inc. Non-current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.00, a 0.00% change year over year.
Third Harmonic Bio Inc. Non-current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.00.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends